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OBJECTIVES This analysis was performed to assess whether beta-adrenergic blocking agent use is
associated with reduced mortality in the Studies of Left Ventricular Dysfunction (SOLVD)
and to determine if this relationship is altered by angiotensin-converting enzyme (ACE)
inhibitor use.
BACKGROUND The ability of beta-blockers to alter mortality in patients with asymptomatic left ventricular
dysfunction is not well defined. Furthermore, the effect of beta-blocker use, in addition to an
ACE inhibitor, on these patients has not been fully addressed.
METHODS This retrospective analysis evaluated the association of baseline beta-blocker use with
mortality in 4,223 mostly asymptomatic Prevention trial patients, and 2,567 symptomatic
Treatment trial patients.
RESULTS The 1,015 (24%) Prevention trial patients and 197 (8%) Treatment trial patients receiving
beta-blockers had fewer symptoms, higher ejection fractions and different use of medications than
patients not receiving beta-blockers. On univariate analysis, beta-blocker use was associated with
significantly lower mortality than nonuse in both trials. Moreover, a synergistic reduction in
mortality with use of both a beta-blocker and enalapril was suggested in the Prevention trial. After
adjusting for important prognostic variables with Cox multivariate analysis, the association of
beta-adrenergic blocking agent use with reduced mortality remained significant for Prevention
trial patients receiving enalapril. Lower rates of arrhythmic and pump failure death and risk of
death or hospitalization for heart failure were observed.
CONCLUSIONS The combination of a beta-blocker and enalapril was associated with a synergistic reduction
in the risk of death in the SOLVD Prevention trial. (J Am Coll Cardiol 1999;33:916–23) ©
1999 by the American College of Cardiology
The Studies of Left Ventricular Dysfunction (SOLVD)
Treatment trial (1) and other studies (2,3) have demon-
strated that angiotensin-converting enzyme (ACE) inhibi-
tors reduce mortality in patients with symptomatic heart
failure. Furthermore, the SOLVD Prevention trial (4)
demonstrated that ACE inhibitors reduced the combined
incidence of death or hospitalization for heart failure in
patients with asymptomatic left ventricular (LV) systolic
dysfunction.
There are a number of reasons why the combined use of
an ACE inhibitor and a beta-adrenergic blocking agent
might improve survival in patients with LV dysfunction to
a greater extent than the use of an ACE inhibitor alone.
Although ACE inhibitors seem to have a modest effect on
reducing arrhythmic deaths (5,6), beta-blockers have potent
antifibrillatory (7,8), anti-ischemic (9) and possibly anti-
thrombotic (10) properties that may reduce the incidence of
sudden cardiac death. Furthermore, some beta-blockers
have vasodilatory (11), antioxidant (12,13) and reverse
remodeling (14–16) properties that would be anticipated to
favorably alter survival. Several trials have suggested that
beta-blockers, in addition to ACE inhibitors, reduce mor-
tality in patients with symptomatic LV dysfunction (17,18).
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However, it is less certain whether beta-blockers confer
additional benefit to asymptomatic patients treated with
ACE inhibitors (19–22).
This analysis was performed to evaluate whether the
baseline use of beta-blockers was independently associated
with reduced mortality in SOLVD and specifically, to
determine whether Prevention trial patients randomized to
enalapril had an incremental reduction in mortality with
beta-blocker use.
METHODS
Studies of left ventricular dysfunction trials. Patients 21
to 80 years of age with no prior history of intolerance to
enalapril and a LV ejection fraction #0.35 measured by
radionuclide angiography, echocardiography or contrast an-
giography were eligible for enrollment in SOLVD (1,4,23).
Those with a recent myocardial infarction (#30 days),
significant valvular heart disease or another serious comor-
bid illness were excluded. The specific inclusion and exclu-
sion criteria have been published (23). All SOLVD partic-
ipants (n 5 6,797) had a detailed evaluation at entry.
Patients were classified as asymptomatic or symptomatic
and were then enrolled in the Prevention or Treatment trial,
respectively (23). There were 4,228 patients in the Preven-
tion trial, approximately one third of whom had New York
Heart Association (NYHA) functional class II symptoms
(4). The Treatment trial included 2,569 patients with
mostly NYHA functional class II and III symptoms (1).
Patients were randomized to enalapril or placebo in each
trial and followed for an average of 35 6 14 and 33 6 15
months in the Prevention and Treatment trials, respectively
(1,4).
Beta-blocker use. Beta-blocker use was determined at the
time of enrollment. Information on the baseline use of
beta-blockers was available for all but five of the Prevention
trial (n 5 4,223) and all but two of the Treatment trial (n 5
2,567) participants. Furthermore, the use of beta-blockers
was neither encouraged nor discouraged in the SOLVD
protocol (23). Information on the specific agents used and
their doses was not collected.
End points. Deaths and hospitalizations for heart failure
were collected for all participants. Causes of death were
evaluated in a masked fashion by the SOLVD investigators
(23) and were classified as due to worsening heart failure
(with or without an arrhythmia), an arrhythmia in the
absence of worsening heart failure, a myocardial infarction,
another cardiovascular cause or a noncardiovascular cause.
For the present analysis, pump failure death includes deaths
classified as “worsening heart failure, with or without
arrhythmia”; arrhythmic deaths include only those deaths
attributed to “arrhythmia without worsening heart failure.”
Coding of variables. Age, heart rate, mean arterial blood
pressure, LV ejection fraction and serum sodium, potassium
and creatinine values were assessed as continuous variables.
The use of beta-blockers, study drug allocation (enalapril/
placebo) and gender were coded dichotomously. New York
Heart Association functional class symptoms were coded as
class I, II or III/IV. The etiology of LV systolic dysfunction
was coded as ischemic or other. All remaining variables were
coded dichotomously, indicating the presence or absence of
a characteristic or the use of a drug at baseline.
Statistical analysis. Continuous characteristics are pre-
sented as mean 6 SD. Pair-wise differences were evaluated
using a chi-square test or t test. Because all-cause mortality
is the most definitive test of a therapeutic agent’s efficacy, it
was used as the primary end point in this analysis, and
separate analyses were performed for the classified modes of
death. As an index of heart failure progression the compos-
ite end point of death or hospitalization for heart failure was
evaluated.
Outcomes were assessed by Kaplan–Meier survival anal-
ysis and the log-rank test statistic. A Cox proportional
hazards model that included baseline beta-blocker use,
study drug allocation, age, gender, NYHA functional class,
LV ejection fraction, etiology of LV dysfunction, history of
prior coronary artery bypass surgery, history of angina or
history of hypertension and the baseline use of diuretics,
digoxin, aspirin and antiarrhythmic drugs was used to
investigate the independent association of beta-blockers
with mortality. This same model, absent study drug alloca-
tion, was used to assess the independent association of
beta-blockers with the predefined end points in patients
randomized to enalapril and placebo. Relative risk (RR)
estimates and 95% confidence intervals (CIs) were obtained
from the Cox models. Two-way interaction between each of
the covariates and beta-blocker use was evaluated. All
analyses were performed using Stata: Release 5.0 (College
Station, Texas).
RESULTS
Prevention trial patient baseline characteristics. Beta-
blockers were used in 1,015 (24%) of the Prevention trial
participants (Table 1). Compared with patients not receiv-
ing beta-blockers, participants who received beta-blockers
were somewhat younger, and were less likely to be women
or have NYHA functional class II symptoms. Furthermore,
patients receiving beta-blockers had slower heart rates,
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CI 5 confidence interval
LV 5 left ventricular
NYHA 5 New York Heart Association
RR 5 relative risk
SAVE 5 Survival and Ventricular Enlargement
SOLVD 5 Studies of Left Ventricular Dysfunction
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lower blood pressure values and higher LV ejection frac-
tions. Patients receiving beta-blockers were also more likely
to have their LV systolic dysfunction classified as due to an
ischemic etiology or have a history of angina or hyperten-
sion, but were less likely to have a history of atrial fibrilla-
tion. Baseline serum potassium levels and the use of anti-
arrhythmic drugs, anticoagulants, aspirin, digoxin and
nitrates were different in the two groups.
Treatment trial patient baseline characteristics. Beta-
blockers were used in only 197 (8%) of the Treatment trial
participants, a rate significantly lower than in the Prevention
trial (p , 0.0001) (Table 2). Compared with patients not
receiving beta-blockers, Treatment trial participants who
received beta-blockers were less likely to have NYHA
functional class III/IV symptoms. Baseline heart rates were
lower, whereas ejection fractions were higher in patients
receiving beta-blockers. Participants receiving beta-blockers
were also more likely to have their LV dysfunction classified
as due to an ischemic etiology, and have a history of angina
or hypertension. The baseline use of aspirin, calcium channel
blocking agents, digoxin and diuretics also differed between
those who did versus those who did not receive beta-blockers.
Modes of death. The incidence of death from any cause
was lower in patients receiving beta-blockers in both trials
(Table 3). In the Prevention trial, most deaths were due to
pump failure or an arrhythmic cause; pump failure ac-
counted for most of the Treatment trial deaths. Prevention
trial participants receiving beta-blockers had a lower death
rate (p , 0.01), due to reductions in arrhythmic (p , 0.05)
and pump failure deaths (p , 0.05), compared with those
not receiving beta-blockers. Likewise, Treatment trial par-
ticipants receiving beta-blockers were less likely to die (p ,
0.01) specifically from pump failure (p , 0.01) compared to
participants not receiving beta-blockers.
Survival curves. As shown in Figure 1, Prevention trial
participants receiving both enalapril and a beta-blocker had
the lowest overall mortality. Prevention trial participants
receiving both therapies were less likely to die compared
with participants receiving enalapril alone (log-rank p 5
0.003), a beta-blocker alone (log-rank p 5 0.03) or neither
of these therapies (log-rank p 5 0.001).
Figure 2 illustrates that Treatment trial participants
receiving both enalapril and a beta-blocker had similar
survival compared with patients receiving a beta-blocker
Table 1. Baseline Characteristics: Prevention Trial Patients
Characteristic Beta-Blocker
No
Beta-Blocker
Number 1,015 3,208
Age (yr) 58 6 10 59 6 10*
Women 9% 12%†
Randomization to enalapril 50.5% 49.7%
NYHA functional class I 70% 66%†
NYHA functional class II 30% 34%
Mean arterial pressure (mm Hg) 93 6 11 94 6 11‡
Heart rate (beats/min) 67 6 11 77 6 12‡
Left ventricular ejection fraction 0.29 6 0.05 0.28 6 0.06‡
Baseline history of
Ischemic etiology 93% 80%‡
Angina 64% 55%‡
Hypertension 49% 33%‡
Coronary artery bypass 30% 30%
Diabetes 16% 15%
Atrial fibrillation 2% 5%*
Baseline use of
Antiarrhythmic drugs 11% 16%‡
Anticoagulants 10% 12%†
Aspirin 60% 53%‡
Calcium channel blocker 49% 49%
Digoxin 7% 14%‡
Diuretics 15% 17%
Nitrates 71% 63%†
Baseline laboratory values
Sodium (mmol/liter) 140 6 3 140 6 3
Potassium (mmol/liter) 4.4 6 0.4 4.3 6 0.4†
Creatinine (mmol/liter) 100 6 23 102 6 25
*p , 0.01. †p , 0.05. ‡p , 0.001.
NYHA 5 New York Heart Association.
Table 2. Baseline Characteristics: Treatment Trial Patients
Characteristic
Beta-
Blocker
No Beta-
Blocker
Number 197 2,370
Age (yr) 61 6 9 61 6 10
Women 17% 20%
Randomization to enalapril 50.1% 49.7%
NYHA functional class I/II 78% 67%*
NYHA functional class III/IV 22% 33%
Mean arterial pressure (mm Hg) 92 6 12 93 6 11
Heart rate (beats/min) 70 6 11 81 6 13†
Left ventricular ejection fraction 0.28 6 0.06 0.25 6 0.07†
Baseline history of
Ischemic etiology 89% 70%†
Angina 73% 57%†
Coronary artery bypass 27% 23%
Hypertension 51% 42%‡
Diabetes 23% 26%
Atrial fibrillation 6% 10%
Baseline use of
Antiarrhythmic drugs 18% 22%
Anticoagulants 12% 16%
Aspirin 41% 33%‡
Calcium channel blocker 48% 33%†
Digoxin 50% 68%†
Diuretics 76% 86%†
Nitrates 73% 75%
Baseline laboratory values
Sodium (mmol/liter) 140 6 3 140 6 3
Potassium (mmol/liter) 4.3 6 0.4 4.3 6 0.5
Creatinine (mmol/liter) 108 6 30 110 6 28
*p , 0.01. †p , 0.05. ‡p , 0.001.
NYHA 5 New York Heart Association.
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alone (log-rank p 5 0.8), but tended to have greater survival
compared with participants receiving enalapril alone (log-
rank p 5 0.06) or neither of these therapies (log-rank p 5
0.005).
Interaction between enalapril and beta-blockers. On
univariate analysis, beta-blocker use was associated with a
significant reduction in the risk of death in both the
Prevention (RR 5 0.77; 95% CI 0.63 to 0.94; p , 0.01) and
in the Treatment trial (RR 5 0.65; 95% CI 0.49 to 0.86;
p , 0.01) (Table 4).
Prevention trial participants receiving enalapril had a
significant unadjusted reduction in the risk of death associ-
ated with beta-blocker use, whereas patients randomized to
placebo did not. Evidence of statistical interaction between
active study drug (enalapril) and beta-blocker use on mor-
tality was present in the Prevention trial (p 5 0.08).
In Treatment trial participants beta-blocker use was
associated with a reduced risk of death, independent of
study drug allocation. No evidence of interaction was
observed in the Treatment trial (p 5 0.70). However, the
small number of patients receiving beta-blockers in this trial
(Table 2) significantly limited the ability to detect interac-
tion.
Table 3. Mortality Rates and Modes of Death
Mode of Death
Beta-Blocker No Beta-Blocker
Deaths Incidence* Deaths Incidence*
Prevention trial
All-cause mortality 12.4% 4.3 15.9% 5.6†
Pump failure 3.3% 1.2 4.9% 1.7‡
Arrhythmic 3.6% 1.3 5.2% 1.8‡
Fatal myocardial infarction 2.5% 0.9 2.3% 0.8
Other cardiovascular 1.3% 0.4 1.5% 0.5
Noncardiovascular 1.7% 0.6 2.1% 0.7
Treatment trial
All-cause mortality 26.9% 8.8 38.2% 14.4†
Pump failure 11.7% 3.8 18.8% 7.1†
Arrhythmic 7.6% 2.5 8.7% 3.3
Fatal myocardial infarction 4.6% 1.5 4.1% 1.6
Other cardiovascular 1.5% 0.5 2.4% 0.9
Noncardiovascular 1.5% 0.5 4.2% 1.6‡
*Incidence rate per 100 person-years of follow-up. †Log rank p value ,0.01. ‡Log rank p value ,0.05.
Figure 1. Unadjusted all-cause mortality survival curves for Pre-
vention trial participants. Patients receiving neither enalapril nor a
beta-blocker (neither) are represented by the broken gray line,
those receiving enalapril alone by the solid gray line, patients
receiving beta-blockers alone by the broken black line and those
receiving both enalapril and a beta-blocker (both) by the solid
black line. The number of patients at risk of death during each
365-day period is shown. Patients with asymptomatic left ventric-
ular dysfunction who received both a beta-blocker and enalapril
had the lowest mortality (p # 0.03).
Figure 2. Unadjusted all-cause mortality survival curves for Treat-
ment trial participants. Patients receiving neither enalapril nor a
beta-blocker (neither) are represented by the broken gray line,
those receiving enalapril alone by the solid gray line, patients
receiving beta-blockers alone by the broken black line and those
receiving both enalapril and a beta-blocker (both) by the solid
black line. The number of patients at risk of death during each
365-day period is shown.
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Adjusted survival. Prevention trial participants receiving
both a beta-blocker and enalapril had a significant, inde-
pendent reduction in the risk of death (Table 5). This
favorable outcome was the result of reductions in cardiovas-
cular deaths (RR 5 0.67; 95% CI 0.48 to 0.94; p 5 0.02),
notably arrhythmic and pump failure deaths. Progression to
symptomatic heart failure, as assessed by the composite end
point of death or hospitalization for heart failure, was also
significantly reduced in Prevention trial participants receiv-
ing beta-blockers and enalapril. In contrast, no significant
independent reduction in the risk of death was associated
with beta-blocker use in Treatment trial participants.
Incremental effect of beta-blockers. In the entire
SOLVD cohort, beta-blocker use was associated with an
incremental mortality reduction in patients receiving enala-
pril. In the prespecified multivariate model, the reduced risk
of death associated with the use of a beta-blocker and
enalapril (RR 5 0.74) was greater than that observed for
beta-blockers alone (RR 5 0.89) or enalapril alone (RR 5
0.88). Figure 1 illustrates the synergistic reduction in mor-
tality observed with the use of both agents in Prevention
trial participants.
Comorbid conditions. Because specific conditions or co-
morbid illnesses probably influenced which patients were or
were not prescribed beta-blockers in SOLVD, we evaluated
whether these covariates altered the association of beta-
blocker use with reduced mortality that was observed in the
Prevention trial (Table 5). The association of beta-blocker
use with reduced mortality in Prevention trial participants
randomized to enalapril was unchanged when history of
previous myocardial infarction (RR 5 0.72; 95% CI 0.53 to
0.98), the presence of atrial fibrillation (RR 5 0.72; 95% CI
0.53 to 0.98) or a history of diabetes (RR 5 0.72; 95% CI
0.53 to 0.97) was added to the multivariate model. Like-
wise, the association of beta-blockers with reduced mortality
in these patients was not significantly altered when use of
calcium channel blockers (RR 5 0.68; 95% CI 0.48 to 0.95)
was added. Moreover, this association remained significant
when all of these covariates (RR 5 0.72; 95% CI 0.50 to
0.99) were collectively added to the multivariate model.
Ischemic and nonischemic subgroups. Although the eti-
ology of LV dysfunction was included in all of the multi-
variate models, we separately assessed the association of
beta-blocker use with mortality in these subgroups, because
some studies have suggested that patients with nonischemic
LV dysfunction derive greater benefit from beta-blockers
(24,25). Due to the relatively small number of patients with
nonischemic LV dysfunction in SOLVD (Tables 1 and 2),
Table 4. Mortality Reduction Associated With the Use of Beta-Blockers in Patients
Randomized to Enalapril and Placebo
Trial
Placebo Enalapril
Number
Relative Risk*
(95% CI) Number
Relative Risk*
(95% CI)
Prevention 2,116 0.91 (0.70 to 1.18) 2,107 0.64 (0.48 to 0.86)†
Treatment 1,282 0.62 (0.41 to 0.93)‡ 1,285 0.69 (0.47 to 1.01)§
*Unadjusted (univariate). †p , 0.01. ‡p , 0.05. §p , 0.10. CI 5 confidence interval.
Table 5. Independent Association of Beta-Blocker Use With Modes of Death and Composite
End Point of Death or Hospitalization for Heart Failure
Mode of Death
Relative Risk* (95% CI)
Placebo Enalapril
All-cause mortality
Prevention trial 0.98 (0.76 to 1.29) 0.70 (0.52 to 0.95)†
Treatment trial 0.79 (0.52 to 1.18) 0.86 (0.58 to 1.27)
Arrhythmic death
Prevention trial 0.85 (0.52 to 1.39) 0.57 (0.32 to 0.99)†
Treatment trial 0.70 (0.31 to 1.59) 1.17 (0.58 to 2.37)
Pump failure death
Prevention trial 1.04 (0.64 to 1.70) 0.54 (0.29 to 1.01)‡
Treatment trial 0.89 (0.49 to 1.60) 0.78 (0.42 to 1.45)
Death or hospitalization for heart failure
Prevention trial 0.89 (0.72 to 1.12) 0.64 (0.49 to 0.83)§
Treatment trial 0.85 (0.62 to 1.17) 0.82 (0.59 to 1.13)
*Multivariate model included use of beta-blocker at baseline, age, gender, New York Heart Association functional class, left
ventricular ejection fraction, etiology of left ventricular dysfunction, history of coronary artery bypass, history of angina, history
of hypertension and use of digoxin, diuretics, aspirin and antiarrhythmic drugs. †p , 0.05. ‡p , 0.10. §p , 0.01. CI 5
confidence interval.
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the Prevention and Treatment trials were combined for this
analysis. Using the same multivariate model, beta-blocker
use tended to be independently associated with reduced
mortality in both patients with ischemic (RR 5 0.80; 95%
CI 0.62 to 1.03; p 5 0.08) and patients with nonischemic
LV dysfunction (RR 5 0.43; 95% CI 0.16 to 1.17; p 5
0.10) who were randomized to enalapril.
DISCUSSION
The present analysis demonstrates that the use of beta-
blockers, in addition to enalapril, is independently associ-
ated with a significant reduction in the risk of death for
patients with asymptomatic LV systolic dysfunction. This
favorable outcome was the result of reductions in arrhyth-
mic death, pump failure death and progression to symptom-
atic heart failure. Moreover, the reduction in mortality
associated with the use of both a beta-blocker and enalapril
was greater than that of either agent alone.
Rationale for a beneficial effect of beta-blockers, in
addition to ACE inhibitors, to reduce arrhythmic death.
Neurohormonal activation occurs in both patients with
asymptomatic (26) and patients with symptomatic (27) LV
systolic dysfunction. Prognosis in these patients is related to
plasma norepinephrine concentrations, with decreased sur-
vival and increased morbidity being associated with higher
catecholamine concentrations (27,28). Furthermore, prefer-
ential activation of cardiac sympathetic outflow in mild
heart failure has been linked to the development of life-
threatening ventricular arrhythmias (29), and increases in
plasma catecholamines in these patients have been observed
to precede the occurrence of sudden cardiac death (30). The
ability of beta-blockers to reduce the direct and indirect
impact of catecholamines on the human heart (13) seems to
be an important mechanism for the reduced incidence of
sudden cardiac death in patients with moderately symptom-
atic LV dysfunction treated with carvedilol (17). Most
important, because the susceptibility to ventricular fibrilla-
tion, at least in the setting of acute ischemia, is related to
functional alterations in the beta2 receptor (8), nonselective
agents such as carvedilol may be particularly effective in
reducing arrhythmic deaths.
Effect on remodeling. Although myocardial remodeling is
initially an adaptive response, it results in progressive LV
dysfunction in the long term (31). Myocyte hypertrophy,
apoptosis, alterations in the extracellular matrix and in-
creases in alpha- and beta-adrenergic activity are all features
of this process (13,32). Furthermore, circulating cat-
echolamines have been demonstrated to have direct toxic
effects on the heart (33), and a variety of inflammatory
cytokines have been shown to be elevated in patients with
LV dysfunction (32), including the patients in SOLVD
(34). Both ACE inhibitors (35) and beta-blockers (13) have
been shown to favorably alter these processes. However,
because these agents act through different mechanisms,
their combination might be anticipated to be additive or
possibly synergistic. The association of beta-blocker use
with reductions in death from pump failure and death or
hospitalization for heart failure in Prevention trial patients
receiving enalapril supports the notion that beta-blockers
reduce the progression to overt heart failure in patients with
asymptomatic LV dysfunction already receiving an ACE
inhibitor.
Synergistic effect of combination therapy. Qualitative
interactions, differences in direction of effect, are infre-
quently observed when subgroups in clinical trials are
analyzed because the smaller sample sizes limit the power to
detect these effects (36). However, when a qualitative
interaction is observed, it likely represents a true effect (36).
The observed association of beta-blocker use with reduced
mortality in the Prevention trial patients randomized to
enalapril was present in both the univariate (unadjusted) and
multivariate (adjusted) models. Furthermore, the beneficial
association of beta-blockers was observed for arrhythmic
death, pump failure death and the composite end point of
death or hospitalization for heart failure. Finally, similar
point estimates were obtained when additional, potentially
confounding covariates were individually and collectively
added to the prespecified multivariate model. These find-
ings suggest that the association between beta-blocker use
and reduced mortality in Prevention trial patients receiving
enalapril is likely a true effect.
Differential effect in prevention trial. The clinical use of
beta-blockers has expanded significantly since the inception
and conduct of the SOLVD trials. It is probable that most
patients treated with beta-blockers in SOLVD received
these agents for ancillary medical conditions, such as coro-
nary artery disease, hypertension or rate control of atrial
fibrillation, rather than LV dysfunction. Furthermore, in the
late 1980s, when SOLVD was conducted, beta-blockers
were largely avoided in patients with more significant
symptoms or pronounced LV dysfunction (37,38). The less
frequent use of beta-blockers in Treatment trial patients
supports this. Also, Treatment trial participants receiving
beta-blockers would be anticipated to be healthier than
those who did not receive these agents in that trial. The
finding that beta-blockers were associated with a significant
reduction in mortality on univariate analysis, but not after
adjustment for important, potentially confounding variables
supports this notion as well. However, because patients in
the Prevention trial were largely asymptomatic and had
higher LV ejection fractions, the use of beta-blockers would
be expected to be less related to the underlying degree of LV
dysfunction. The observed similar associations of beta-
blocker use with reduced mortality on univariate and mul-
tivariate analysis in the Prevention trial patients support this
contention.
Beta-blocker use. Beta-blocker use was assessed at the
time of enrollment in SOLVD. Although the use of these
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agents and other medications probably changed during
follow-up, it seems unlikely that this introduced a system-
atic bias into the present analysis.
Comparison with other studies. The Survival and Ven-
tricular Enlargement (SAVE) trial randomized 2,231 pa-
tients with a recent (3 to 16 days) myocardial infarction and
radionuclide LV ejection fraction #0.40 to captopril or
placebo (39). A post hoc analysis of SAVE demonstrated an
independent association of beta-blocker use with reduced
cardiovascular mortality (RR 5 0.70; 95% CI 0.56 to 0.88)
and progression to symptomatic heart failure (RR 5 0.82;
95% CI 0.71 to 0.96) over an average follow-up of 42 6 10
months (19). Although no evidence of interaction between
beta-blocker use and captopril was reported, the relatively
small size of SAVE limited the power to detect such an
effect (36).
The Australia–New Zealand Heart Failure trial random-
ized 415 patients with asymptomatic (30%) or symptomatic
LV dysfunction, defined by a radionuclide LV ejection
fraction #0.45, to carvedilol or matching placebo (20). The
primary end point of this trial was change in LV ejection
fraction. Most patients (86%) received concurrent ACE
inhibitor therapy, and the average follow-up was 19 months.
After one year of follow-up, patients receiving carvedilol
had a significant (125%) improvement in LV ejection
fraction compared with placebo patients (15%; p 5 0.001).
Furthermore, patients randomized to carvedilol had a 26%
reduction in the risk of death or hospitalization compared to
participants receiving placebo (p 5 0.02). The small size of
this trial did not permit separate analyses of the symptom-
atic and asymptomatic groups.
Limitations. The present analysis is not a randomized
comparison of outcome in patients who did versus those who
did not receive concomitant beta-blocker therapy. Although
adjustments were made for relevant differences, it is possible
that the groups differed in other respects. However, the
SOLVD cohort is a well characterized group of patients
with comprehensive, long-term follow-up. Although resid-
ual confounding cannot be definitively excluded, the multi-
variate model allowed us to adjust for important prognostic
variables. Moreover, the association between beta-blocker
use and reduced mortality in Prevention trial participants
receiving enalapril was consistent for all of the end points
evaluated. Likewise, the point estimates for the effect of
beta-blockers were similar when additional covariates were
added to the prespecified multivariate model.
Although trends similar to those found in the Prevention
trial were noted in Treatment trial participants, the small
number of subjects receiving beta-blockers in the Treatment
trial precludes a definitive statement regarding the benefit or
lack of benefit in this group. Whether beta-blockers alter
mortality in patients with NYHA class III or IV heart
failure is unclear (22). Recent overviews of randomized trials
suggest that beta-blockers reduce mortality in these patients
(18,40). In addition, the Second Cardiac Insufficiency
Bisoprolol Study (CIBIS II), a large (N 5 2,647) random-
ized trial of bisoprolol versus matched placebo in patients
with NYHA class III or IV heart failure, recently reported
a prominent reduction in mortality with the use of bisopro-
lol (RR 5 0.66; 95% CI 0.54 to 0.81; p , 0.0001).
Moreover, this mortality reduction was primarily the result
of a 44% decrease in the incidence of sudden death (41).
Conclusions. The use of beta-blockers, in addition to
ACE inhibitor therapy, was associated with a significant,
independent reduction in the risk of death in SOLVD
Prevention trial participants. This favorable outcome was
the result of reductions in arrhythmic death and pump
failure death. Progression to symptomatic heart failure was
also significantly reduced in Prevention trial patients receiv-
ing both a beta-blocker and enalapril. Therefore, the com-
bination of a beta-blocker and enalapril was associated with
a synergistic reduction in mortality of patients with asymp-
tomatic LV dysfunction in SOLVD.
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